02.13.25 -- Tech Vendors Are Today's Don Quixotes

Leveraging a CDMO to oversee all aspects of analytical method development is crucial for achieving speed in clinical trials, regulatory approval, and commercial launch.

Leveraging incurred sample reanalysis (ISR) in your quality control helps your team mitigate risks, establish regulatory compliance, and instill confidence in your pharmacokinetic modeling.

Watch to discover the key benefits of outsourcing your OSD production and explore real-world examples and best practices to help you streamline your processes and enhance your operational agility.

Our extensive oncology expertise coupled with an end-to-end approach helps accelerate your clinical programs, giving you the confidence to bring breakthrough treatments to patients.

Explore the rapidly evolving regulatory landscape that pharmaceutical and biotech industries face as they integrate AI and advanced technologies into safety, compliance, and lifecycle management.

Explore the history of AI, gain clarity on key concepts, address common questions, and discover its transformative role in drug development, with insights into its current and future impact on the industry.

Looking ahead to 2025, clinical trials will evolve with new technologies, regulatory shifts, and emerging therapies. Explore key trends shaping the future of the industry.

Answering questions about the potential of oncolytic virus therapies, how they integrate with combination therapies, the regulatory landscape, and how it varies globally.

The Trial Master File (TMF) landscape in 2025 will require companies to stay attuned to the evolving ICH E6(R3) guidelines and the full implementation of the CTIS.